Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Complement System01:27

Complement System

10.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.5K
Complementation Tests00:49

Complementation Tests

6.2K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.2K
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups

29.8K

Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
29.8K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

1.1K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hyperoside exposure impairs cardiac development in zebrafish embryos: Evidence from phenotyping, transcriptomics, and antioxidant rescue.

Toxicology and applied pharmacology·2026
Same author

HSP90AA1 Facilitates Vascular Calcification in Chronic Kidney Disease Involving Chaperone-Mediated Autophagy.

Biomedicines·2026
Same author

Factors influencing patency after percutaneous transluminal angioplasty for autogenous arteriovenous fistulae: a systematic review and meta-analysis.

Renal failure·2026
Same author

Benefits of physical exercises in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Renal failure·2026
Same author

Quantitative Glycoproteomics Reveals Distinctive <i>N</i>-Glycosylation Patterns in Human Kidney Tissues with Minor Glomerular Abnormalities.

Journal of proteome research·2026
Same author

Pressure cycling technology-assisted data-independent acquisition proteomics reveals molecular alterations and potential therapeutic targets in minor glomerular abnormalities.

Precision clinical medicine·2026
Same journal

Unsupervised Clustering Identifies High-Risk Phenotypic Subgroup in Crescentic Glomerulonephritis Patients.

Kidney diseases (Basel, Switzerland)·2026
Same journal

Association of Body Composition-Related Indicators with Urinary Protein Levels and Proteinuria Remission in Patients with Primary Membranous Nephropathy.

Kidney diseases (Basel, Switzerland)·2026
Same journal

Development and Validation of a Multivariable Nomogram Predictive of Kidney Function after Cardiopulmonary Resuscitation.

Kidney diseases (Basel, Switzerland)·2026
Same journal

Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series.

Kidney diseases (Basel, Switzerland)·2026
Same journal

Decade-Long Trends in Chronic Kidney Disease-Mineral and Bone Disorder Target Achievement and Mortality Associations among Chinese Hemodialysis Patients: Insights from the China DOPPS Study.

Kidney diseases (Basel, Switzerland)·2026
Same journal

Monthly versus Bimonthly Bioelectrical Impedance Analysis for Dry Weight Assessment and Intradialytic Hypotension: A Randomized Crossover Trial.

Kidney diseases (Basel, Switzerland)·2026
查看所有相关文章

相关实验视频

Updated: Jan 30, 2026

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K

针对IgA脏病的补充向疗法的进展

Min Lu1, Guisen Li1

  • 1Department of Nephrology and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Kidney diseases (Basel, Switzerland)
|January 29, 2026
PubMed
概括
此摘要是机器生成的。

抗体A脏病 (IgAN) 涉及补体系统,特别是替代途径. 补充向疗法对Igan治疗有希望,但需要进一步研究患者选择和疗效.

关键词:
另一个替代路径.补充抑制剂的补充抑制剂在IgA脏病发作中,IgA脏病发作莱克通道的路径

更多相关视频

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
12:38

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

6.6K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

939

相关实验视频

Last Updated: Jan 30, 2026

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K
Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
12:38

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies

Published on: July 19, 2007

6.6K
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
11:12

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies

Published on: September 13, 2024

939

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • IgA脏病 (IgAN) 是中国年轻人的功能衰竭的主要原因.
  • 疾病异质性使针对IGAN的向药物开发复杂化.
  • 人们越来越认识到补体系统在IgAN病变发生中的作用.

研究的目的:

  • 审查IgA脏病和补充系统之间的关联.
  • 总结对IGAN的补充向疗法的进展.
  • 讨论这个治疗领域的挑战和未来方向.

主要方法:

  • 对IGAN和补充系统相互作用的文献进行系统审查.
  • 在IGAN病变发生过程中分析了四次命中假说.
  • 对IgAN.Complement抑制剂的当前临床试验数据的评估.

主要成果:

  • 替代补充途径是IGAN的关键贡献者,尽管其他途径也参与其中.
  • 一些针对级联的补充抑制剂正在临床试验中,有效性各不相同.
  • 挑战包括患者分层,长期安全性和成本效益.

结论:

  • 补充向疗法为IGAN提供了一种新的治疗策略.
  • 克服患者选择的障碍和证明长期疗效至关重要.
  • 开发生物标志物和进行大规模试验是精密治疗的必要条件.